"Key Takeaways from CHMP's October 2023 Meeting | European Medicines Agency"

The European Medicines Agency's Committee for Medicinal Products Human Use (CHMP) recommended seven new medicines for approval, including treatments for Duchenne muscular dystrophy, relapsed or refractory multiple myeloma, and hyperargininemia. The committee also granted extensions of therapeutic indications for eight medicines and initiated a review of the benefits and risks of a medicine used to treat primary biliary cholangitis.